U.S. Markets open in 1 hr 8 mins

Citius Pharmaceuticals, Inc. (CTXR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.0300+0.0500 (+2.53%)
At close: 4:00PM EDT
2.0300 0.00 (0.00%)
Pre-Market: 08:00AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.9800
Open2.0446
Bid2.0600 x 28000
Ask2.0800 x 4000
Day's Range2.0000 - 2.0600
52 Week Range0.8730 - 4.5600
Volume1,949,689
Avg. Volume7,601,704
Market Cap275.012M
Beta (5Y Monthly)1.53
PE Ratio (TTM)N/A
EPS (TTM)-0.3450
Earnings DateAug 12, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Citius Pharmaceuticals to Join Benzinga All Access Show on Friday, September 17, 2021

    Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products and stem cell therapies, today announced that it will be joining Benzinga's All Access Show for a 20-minute interview on Friday, September 17, 2021 at 10:10 am ET.

  • Zacks

    Citius (CTXR) Acquires Dr. Reddy's License for NHL Therapy

    Citius Pharmaceuticals (CTXR) acquires Dr. Reddy's exclusive license rights for E7777 to treat a rare form of NHL and other cancer indications.

  • PR Newswire

    Citius Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15

    Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products and stem cell therapies, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.